2025 HCPCS Code G9071
Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i or stage iia-iib; or t3, n1, m0; and er and/or pr positive; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
TAGS: demonstration disease stage ductal metastases female carcinoma invasive breast predominant adenocarcinoma evidence cancer include| Short Description | Onc dx brst stg1-2b hr,nopro |
| HCPCS Action Code | N - No maintenance for this code |
| HCPCS Coverage Code | C - Carrier judgment |
| HCPCS Code Added Date | January 01, 2006 |
| HCPCS Action Effective Date | January 01, 2007 |
| HCPCS Pricing Indicator Code | 00 - Service not separately priced by part B (e.G., services not covered, bundled, used by part a only, etc.) |
| HCPCS Type Of Service Code | 1 - Medical care |
| HCPCS Multiple Pricing Indicator Code | 9 - Not applicable as HCPCS not priced separately by part B (pricing indicator is 00) or value is not established (pricing indicator is '99') |
| HCPCS Anesthesia Base Unit Quantity | 0 |
| HCPCS Coverage Issues Manual Reference Section Number |
Check Similar HCPCS Codes
- G1008 - Cdsm cranberry pk
- G1009 - Cdsm sage health
- G1010 - Cdsm stanson
- G1011 - Cdsm qualified nos
- G1012 - Cdsm agilemd
- G1013 - Cdsm evidencecare
- G1014 - Cdsm inveniqa
- G1015 - Cdsm reliant
- G1016 - Cdsm speed of care
- G1017 - Cdsm healthhelp
- G1018 - Cdsm infinx
- G1019 - Cdsm logicnets
- G1020 - Cdsm curbside
- G1021 - Cdsm ehealthline
- G1022 - Cdsm intermountain
- G1023 - Cdsm persivia
- G1024 - Cdsm radrite
- G1025 - Pt mnth 1 mcp prov
- G1026 - Pt hemo > 3mo
- G1027 - Pt hemo < 3mo
